STAT+: Merck-Kelun lung cancer drug cut risk of tumor progression by 65%, ASCO abstract shows

Merck and China-based Kelun-Biotech's drug sacituzumab tirumotecan demonstrated a 65% reduction in tumor progression risk in Phase 3 lung cancer trials. The study represents the first successful combination of an antibody-drug conjugate with PD-1 immunotherapy in advanced non-small cell lung cancer patients, with preliminary survival benefits observed.